Core Viewpoint - The controversy surrounding the product Ergothioneine from Kolun Pharmaceutical is primarily focused on its classification as a dietary supplement rather than a drug, which has led to accusations of it being a "fake drug" by a prominent biologist [1][2]. Group 1: Product Classification and Controversy - Kolun Pharmaceutical asserts that Ergothioneine is recognized internationally as a dietary supplement and not a drug, countering claims of it being a "fake drug" [1]. - The core of the dispute revolves around the product's qualifications, with Kolun responding to criticisms regarding the lack of drug approval by citing studies published in the high-impact journal "Cell Metabolism" that support its health benefits [1]. Group 2: Safety and Regulatory Status - Ergothioneine has been classified as a new type of food supplement or functional health food ingredient in developed countries, receiving GRAS certification from the FDA and approval from the European Food Safety Authority [2]. - Kolun Pharmaceutical has submitted an application for Ergothioneine as a new food ingredient to the National Health Commission, which is currently under review [2]. - The company welcomes scrutiny from the academic community, regulatory bodies, and consumers regarding its research and products, advocating for an objective perspective on emerging technologies [2].

Core Viewpoint - The core controversy revolves around whether the product Ergotioneine capsules from Kelun Pharmaceutical is a dietary supplement or a "fake drug" as claimed by Peking University’s Rao Yi [1][4]. Group 1: Company Position - Kelun Pharmaceutical asserts that Ergotioneine is recognized internationally as a dietary supplement and not a drug, thus challenging the notion of it being labeled as a "fake drug" [1][4]. - The company emphasizes that the value and safety of Ergotioneine have been scientifically validated through various studies, including those published in top journals [2][3]. - Kelun Pharmaceutical calls for an objective industry perspective on emerging technologies to shift the nutrition and health industry from a marketing-driven approach to a science-driven one [1][6]. Group 2: Scientific Evidence - The company cites two studies published in "Cell Metabolism" demonstrating that Ergotioneine can significantly extend the lifespan of model organisms and improve their physical performance [2]. - Additional clinical research indicates that Ergotioneine may help reduce sleep difficulties, improve cognitive functions in patients with mild cognitive impairment, decrease skin wrinkles, and lower the risk of coronary artery disease [3]. - The safety of Ergotioneine has been established in toxicity tests and randomized controlled trials, with its acceptance as a new food supplement in developed countries [3]. Group 3: Market Performance - Despite the controversy, Kelun Pharmaceutical's Ergotioneine products continue to be sold, with prices ranging from 1,199 yuan to 4,476 yuan, and sales exceeding 18.83 million yuan as of June 5 [5].

Group 1: Tesla and Elon Musk - Trump expressed disappointment in Musk, indicating a potential rift in their relationship, which could impact Tesla's market perception [2][20] - Following Trump's comments, Tesla's stock plummeted, resulting in a market value loss of approximately $100 billion, with a 14.26% drop in share price [20][21] Group 2: Pharmaceutical Industry - Controversy arose around the drug Ergotamine, with a prominent figure claiming it is a "fake drug," leading to public scrutiny of its efficacy and the marketing practices of Kolun Pharmaceutical [7] - Kolun Pharmaceutical defended its product, stating positive feedback from users, despite the ongoing debate regarding regulatory compliance [7] Group 3: Consumer Goods - The "1.5 bucket" product from Jinmailang faced criticism for misleading marketing, as the actual weight did not meet the advertised quantity, raising concerns about consumer trust [8][10] - The controversy follows a similar issue with another brand, indicating a trend of scrutiny in the instant noodle market regarding product labeling and consumer perception [8][10] Group 4: Technology Partnerships - Xiaopeng Motors and Huawei announced a collaboration on AR-HUD technology, which is expected to enhance the automotive experience and benefit related supply chain companies [23] - This partnership marks a significant step in the integration of advanced technology in vehicles, potentially influencing market dynamics in the automotive sector [23] Group 5: Apple and Tata Group - Apple has transferred its iPhone and MacBook repair services in India to Tata Group, indicating a strategic move to strengthen its operational capabilities in the region [22] - This transition reflects Apple's ongoing commitment to expanding its presence in the Indian market, despite previous pressures from political figures [22] Group 6: Aviation Industry - Airbus is reportedly in discussions with Chinese airlines for a potential order of up to 500 aircraft, which could significantly impact the aviation market and Airbus's sales figures [26] - The negotiations highlight China's growing demand for new aircraft as it continues to modernize its aviation fleet [26] Group 7: Defense Industry - Indonesia is evaluating the procurement of Chinese-made J-10 fighter jets, focusing on performance and cost-effectiveness, which could reshape regional defense dynamics [26] - This consideration reflects Indonesia's ongoing military modernization efforts and its search for high-value defense equipment [26]

Core Viewpoint - The controversy surrounding Kelun Pharmaceutical and its chairman Liu Gexin has intensified due to allegations regarding the efficacy and regulatory status of its anti-aging product, Ergothioneine, which has not received official certification as a health product in China [1][2][4]. Financial Performance - In Q1 2025, Kelun Pharmaceutical reported a significant revenue decline of 29% year-on-year, totaling 4.39 billion yuan, while net profit plummeted by 43% to 584 million yuan, marking the worst quarterly performance in five years [5][6]. - The company's traditional infusion business revenue fell below 9 billion yuan, a record low, contributing to the overall financial downturn [5][6]. - The cash flow from operating activities also dropped over 60%, reaching 450 million yuan, indicating severe operational challenges [5]. Product Controversy - Ergothioneine, marketed as an anti-aging supplement, lacks regulatory approval and has not been substantiated by scientific evidence for its claimed benefits, raising compliance and ethical concerns [2][3][4]. - The product is being sold through cross-border e-commerce channels, exploiting regulatory differences between domestic and international markets [3][4]. Business Strategy and Challenges - The chairman has positioned the anti-aging sector as the "fourth entrepreneurial venture" for the company, following its traditional infusion and antibiotic businesses, aiming to create an ecosystem around anti-aging products [6][7]. - The subsidiary, Chuaning Biological, which was expected to drive growth through synthetic biology, has seen its revenue contribution remain minimal, indicating slow progress in its transformation strategy [7]. Market Environment - The pharmaceutical industry is facing significant challenges due to stringent government policies, such as the "limit on antibiotics" directive, which has adversely affected the infusion market and overall demand [6][7]. - Despite the decline in traditional business, non-infusion segments (generic and innovative drugs) showed some growth, but this was insufficient to offset the losses from the core infusion business [6].

Core Viewpoint - The article discusses the controversy surrounding Kelun Pharmaceutical's new product, Ergothioneine capsules, which has been labeled as a "fake drug" by a prominent biologist, leading to a significant drop in the stock prices of both Kelun Pharmaceutical and its subsidiary, Chuaning Biological. Company Summary - Kelun Pharmaceutical's chairman, Liu Gexin, promoted Ergothioneine capsules, resulting in a stock price increase of 16.75% for Kelun and 12.22% for Chuaning Biological over the past month [1][3] - Following the criticism from biologist Rao Yi, both companies experienced a stock price decline of 4.96% and 1.98%, respectively, closing at 37.75 CNY per share and 12.87 CNY per share, with market capitalizations of 603.27 billion CNY and 287.01 billion CNY [5] - Ergothioneine is a natural antioxidant derived from microorganisms, particularly edible mushrooms, and has been associated with various health benefits [5][6] Industry Summary - The product Ergothioneine has not yet been approved as a health supplement in China, and there are no registered products containing Ergothioneine found in the National Medical Products Administration's database [6][9] - The product is currently being sold in China through cross-border e-commerce after being exported to Japan for production, as it has not received domestic approval [6] - Ergothioneine's potential for oral consumption remains uncertain, as it is primarily used as a bioactive ingredient in cosmetic formulations [6]

Core Viewpoint - The controversy surrounding the drug ergothioneine, labeled as a "fake drug" by a prominent biologist, has led to a response from Kelun Pharmaceutical, asserting the scientific validity of the product despite the criticism [1] Company Response - Kelun Pharmaceutical's staff stated that the company has never claimed ergothioneine to be a drug and believes the articles criticizing it have misrepresented the facts [1] - The company emphasizes that there is clear scientific research and clinical evidence supporting the efficacy of ergothioneine overseas [1] Market Reaction - Following the negative publicity, the company's stock experienced a significant decline, which the staff described as a normal market fluctuation and not directly linked to the controversy [1]

Group 1 - The pharmaceutical sector has recently experienced a significant pullback, with the innovative drug concept seeing a net outflow of nearly 2.5 billion yuan in A-shares [1] - The Tianhong Innovative Drug ETF (517380) reached a new high for the year before experiencing a substantial decline, dropping 2.75% with a trading volume of 22 million yuan, and most constituent stocks fell nearly 5% [1] - The Tianhong Innovative Drug ETF is the only product tracking the Hang Seng-Hu-Shen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] Group 2 - Dongwu Securities predicts that 2025 will mark the explosive growth of China's innovative drug industry, driven by three core factors: significant BD transactions, profitability turning points for leading companies, and an improving policy environment [2] - Guosheng Securities acknowledges short-term trading pullback risks but emphasizes the solid underlying logic and clear trends in the innovative drug sector, maintaining a positive outlook for the innovative drug bull market [2] - The market size of China's innovative drugs is expected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2]

Group 1 - The company announced a share placement agreement involving its subsidiary, Sichuan Kelun Biotech Co., Ltd., to issue 5,918,000 H shares at a price of HKD 331.8 per share [1][2] - The net proceeds from the placement are expected to be HKD 1.943 billion, which will be used for product research and development, clinical trials, registration, manufacturing, commercialization, and enhancing internal R&D capabilities [1][2] - The completion of the placement is subject to certain conditions outlined in the placement agreement, indicating uncertainty regarding the timing and completion of the transaction [1] Group 2 - If the placement is successfully completed, the total shares of Kelun Biotech will change, with the company remaining the controlling shareholder with approximately 53.41% of the shares [2] - The placement aims to meet the funding needs for the continuous development and business growth of Kelun Biotech, thereby broadening its financing channels and positively impacting its operations and long-term development [2]

高乐股份：副总经理杨其新辞职 华锋股份：收到第二期土地收储补偿款1496万元 科伦药业（002422）公告，控股子公司科伦博泰于2025年6月5日与2名配售代理订立配售协议，配售 591.8万股H股，配售价格为331.8港元/股，所得款项净额预计为19.43亿港元。配售完成后，科伦博泰股 份总数将变更为2.33亿股，公司及全资子公司科伦国际发展有限公司合计直接持有科伦博泰约53.41%股 份，仍为控股股东。此次配售旨在满足科伦博泰持续发展与业务增长所需资金需求，进一步拓宽其融资 渠道，对公司及科伦博泰的经营和长期发展有积极影响。 华锋股份（002806）公告，公司于2025年6月4日收到肇庆市端州区土地储备中心支付的第二期土地收储 补偿款1496万元。公司与端州储备中心已正式签署《土地收回协议书》，并办理完成产权过户登记手 续。本次土地收储事项不会对公司正常生产运营造成不利影响，不存在损害公司及股东权益的情形。 科伦药业：控股子公司科伦博泰配售591.8万股H股 高乐股份（002348）公告，公司副总经理杨其新因个人原因辞职，辞职报告自送达董事会时生效。杨其 新辞职后将不再担任公司及控股子公司任何职务。杨其新 ...

证券代码：002422 证券简称：科伦药业 公告编号：2025-046 特别风险提示： 本次配售的完成取决于配售协议约定的若干先决条件的达成，是否完成及最 终完成的时间存在不确定性，提请投资者注意投资风险。 四川科伦药业股份有限公司（以下简称"公司"）近日获悉公司控股子公司 四川科伦博泰生物医药股份有限公司（以下简称"科伦博泰"）根据其股东大会 的发行股份的一般性授权，于2025年6月5日与2名配售代理订立配售协议，根据 协议约定，配售代理同意促使向不少于6名承配人配售5,918,000股科伦博泰H股 股份，配售价格为331.8港元/股（以下简称"本次配售"），本次配售的完成取 决于配售协议约定的若干先决条件的达成。 本次配售所得款项净额预计为19.43亿港元，将用于科伦博泰的（1）产品的 研发、临床试验、注册备案、制造及商业化；（2）提升内部研发技术能力、加 强外部合作及拓展产品管线组合；（3）补充营运资金及作一般企业用途。 四川科伦药业股份有限公司 关于控股子公司科伦博泰根据一般性授权配售股份的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 本次配售 ...